Prognostic Factors in Lenvatinib-Treated Differentiated Thyroid Cancer: A Real-World Study with Extended Follow-Up
BACKGROUND: Lenvatinib is a standard first-line treatment for progressive radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), but real-world outcomes over extended follow-up and prognostic factors remain insufficiently characterized. METHODS: We retrospectively analyzed 97 patients with progressive RAI-R DTC treated with lenvatinib at a single institution between 2015 and 2024. Patients with anaplastic or medullary thyroid carcinoma and those treated for less than six months were excluded. Progression-free survival (PFS) and overall survival (OS) were evaluated using the Kaplan-Meier method, and prognostic factors were assessed using Cox proportional hazards models. RESULTS: Median age at treatment initiation was 68 years, and 38% of patients had bone metastases. With a median follow-up of 36 months, median PFS and OS were 25 months (95% confidence interval [CI], 21-31) and 59 months (95% CI, 45-82), respectively. The objective response rate was 58%, and the disease control rate was 97%. Multivariate analysis identified older age as an independent predictor of shorter PFS (Hazard ratio [HR] 1.34 per decade of age, p<0.01) and OS (HR 1.63 per decade of age, p<0.005). Bone metastasis was independently associated with worse OS (HR 2.25, p<0.05) but not PFS. Receiver operating characteristic analyses suggested age cutoffs of approximately 70 years. Bone metastasis was associated with significantly poorer OS among older patients. CONCLUSIONS: Lenvatinib provided durable disease control in patients with RAI-R DTC. Older age at treatment initiation and bone metastasis were independent determinants of survival and may help guide risk stratification and treatment timing in clinical practice.
Authors
- Kiminori Sugino (ORCID: https://orcid.org/0000-0002-9692-9871)
- Kiyomi Yamada Hames
- Ritsuko Okamura
- Kenichi Matsuzu
- Akifumi Suzuki (ORCID: https://orcid.org/0000-0002-8555-9238)
- Chie Masaki (ORCID: https://orcid.org/0000-0002-5959-6182)
- Kana Yoshioka
- Junko Akaishi (ORCID: https://orcid.org/0000-0002-9917-2456)
- Chisato Tomoda (ORCID: https://orcid.org/0000-0002-3665-6576)
- Wataru Kitagawa
- Yoshiyuki Saito
- Koichi Ito
Institutions
- Ito Hospital (JP)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1530/etj-26-0231
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00